SG11201408347UA - Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides - Google Patents

Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides

Info

Publication number
SG11201408347UA
SG11201408347UA SG11201408347UA SG11201408347UA SG11201408347UA SG 11201408347U A SG11201408347U A SG 11201408347UA SG 11201408347U A SG11201408347U A SG 11201408347UA SG 11201408347U A SG11201408347U A SG 11201408347UA SG 11201408347U A SG11201408347U A SG 11201408347UA
Authority
SG
Singapore
Prior art keywords
san diego
international
road
receptor ligand
nuclear receptor
Prior art date
Application number
SG11201408347UA
Inventor
Ying Sun
Ning Zou
Amha Hewet
Jason K Pinkstaff
Shailaja Srinagesh
Richard S Barnett
Feng Tian
Anna-Maria A Hays Putnam
Marco Gymnopoulos
Nick Knudsen
Andrew Beck
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of SG11201408347UA publication Critical patent/SG11201408347UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 December 2013 (19.12.2013) WIPOIPCT (10) International Publication Number WO 2013/188740 A1 (51) International Patent Classification: A61K 47/48 (2006.01) C07K16/30 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/045834 14 June 2013 (14.06.2013) English English (30) Priority Data: 61/659,937 61/766,564 61/806,338 14 June 2012 (14.06.2012) US 19 February 2013 (19.02.2013) US 28 March 2013 (28.03.2013) US (71) Applicant: AMBRX, INC. [US/US]; 10975 North Torrey Pines Road, Suite 100, La Jolla, CA 92037 (US). (72) Inventors: SUN, Ying; 14972 Avenida Venusto #65, San Diego, CA 92128 (US). ZOU, Ning; 9829 Fieldthorn Street, San Diego, CA 92127 (US). HEWET, Amha; 1170 La Vida Court, Chula Vista, CA 91915 (US). PINK- STAFF, Jason, K.; 2095 Wandering Road, Encinitas, CA 92024 (US). SRINAGESH, Shailaja; 3877 Pell Place, Unit 104, San Diego, CA 92130 (US). BARNETT, Richard, S.; 306 Belmont Court, San Marcos, CA 92069 (US). TIAN, Feng; 8374 Orange Haven Place, San Diego, CA 92129 (US). PUTNAM, Anna-Maria, A. Hays; 11522 Cesped Drive, San Diego, CA 92124 (US). GYM- NOPOULOS, Marco; 3620 3rd Avenue, San Diego, CA 92103 (US). KNUDSEN, Nick; 1916 Rohn Road, Escon- dido, CA 92025 (US). BECK, Andrew; 4732 Kansas Street, Apt. 2, San Diego, CA 92116 (US). (74) Agent: WALLEN, III, John W.; 10975 North Torrey Pines Road, Suite 100, La Jolla, California 92037 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) © •t l> 00 00 i-H o CJ (54) Title: ANTI-PSMA ANTIBODIES CONJUGATED TO NUCLEAR RECEPTOR LIGAND POLYPEPTIDES (57) Abstract: This invention relates anti-prostate-specific membrane antigen antibodies to (aPSMA) and aPSMA antibody • ar receptor ligand (NRL) conjugates comprising at least one non-naturally-encoded amino acid. nucle -
SG11201408347UA 2012-06-14 2013-06-14 Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides SG11201408347UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261659937P 2012-06-14 2012-06-14
US201361766564P 2013-02-19 2013-02-19
US201361806338P 2013-03-28 2013-03-28
PCT/US2013/045834 WO2013188740A1 (en) 2012-06-14 2013-06-14 Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides

Publications (1)

Publication Number Publication Date
SG11201408347UA true SG11201408347UA (en) 2015-01-29

Family

ID=48670867

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408347UA SG11201408347UA (en) 2012-06-14 2013-06-14 Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides

Country Status (11)

Country Link
US (1) US20150152187A1 (en)
EP (1) EP2861259A1 (en)
JP (1) JP2015521602A (en)
KR (1) KR20150023729A (en)
CN (1) CN104619350A (en)
AU (1) AU2013274078A1 (en)
CA (1) CA2876706A1 (en)
IL (1) IL236147A0 (en)
MX (1) MX2014015205A (en)
SG (1) SG11201408347UA (en)
WO (1) WO2013188740A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201506443TA (en) 2010-08-17 2015-10-29 Ambrx Inc Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MX347611B (en) 2011-06-19 2017-05-04 Abogen Inc Devices, solutions and methods for sample collection.
DK2907824T3 (en) 2012-10-11 2018-07-23 Daiichi Sankyo Co Ltd ANTIBODY-drug conjugate
ES2782248T3 (en) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Antibody-drug conjugate produced by binding through a linker having a hydrophilic structure
CN104225611B (en) * 2013-06-18 2017-06-30 天津键凯科技有限公司 The conjugate of Dasatinib and non-linear configurations polyethylene glycol
SI3088419T1 (en) 2013-12-25 2019-01-31 Daiichi Sankyo Company Anti-trop2 antibody-drug conjugate
DK3466976T3 (en) 2014-01-31 2021-12-13 Daiichi Sankyo Co Ltd ANTI-HER2-ANTIBODY-MEDICINE CONJUGATE
KR102351755B1 (en) 2014-04-10 2022-01-14 다이이찌 산쿄 가부시키가이샤 Anti-her3 antibody-drug conjugate
ES2754348T3 (en) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugate of (anti-HER2 antibody) -pharmaceutical
CA2947704A1 (en) * 2014-04-10 2015-10-15 Dna Genotek Inc. Method and system for microbial lysis using periodates
AU2016286898B2 (en) 2015-06-29 2022-12-08 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
WO2017069192A1 (en) * 2015-10-21 2017-04-27 和光純薬工業株式会社 Stabilizer and stabilization method
EP4218802A3 (en) * 2016-07-01 2023-09-27 The Board of Trustees of the Leland Stanford Junior University Conjugates for targeted cell surface editing
JP7330101B2 (en) 2016-11-08 2023-08-21 レゲネロン ファーマシューティカルス，インコーポレーテッド Steroids and their protein conjugates
WO2018110515A1 (en) 2016-12-12 2018-06-21 第一三共株式会社 Combination of antibody-drug conjugate and immune checkpoint inhibitor
KR102537651B1 (en) 2017-01-17 2023-05-26 다이이찌 산쿄 가부시키가이샤 Anti-GPR20 Antibodies and Anti-GPR20 Antibody-Drug Conjugates
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
EP3585815A4 (en) * 2017-02-24 2021-03-17 Thomas Jefferson University Methods and compositions for inhibiting tumor growth and enhancing immune responses to tumors
TWI794230B (en) 2017-05-15 2023-03-01 日商第一三共股份有限公司 Anti cdh6 antibodies and anti cdh6 antibody drug conjugates, as well as manufacturing method thereof
MX2019013690A (en) 2017-05-18 2020-01-27 Regeneron Pharma Cyclodextrin protein drug conjugates.
EP3630977B1 (en) 2017-06-02 2024-02-21 Ambrx, Inc. Methods and compositions for promoting non-natural amino acid-containing protein production
CA3073924C (en) 2017-08-31 2023-10-17 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
BR112020003466B1 (en) 2017-08-31 2023-12-12 Daiichi Sankyo Company, Limited COMPOST PRODUCTION METHODS, AND, COMPOST
JP6279801B1 (en) * 2017-09-19 2018-02-14 株式会社らいむ Composition and method for producing the same
MX2020007024A (en) 2018-01-03 2020-10-28 Palleon Pharmaceuticals Inc Recombinant human sialidases, sialidase fusion proteins, and methods of using the same.
JP2021519076A (en) * 2018-03-29 2021-08-10 アンブルックス, インコーポレイテッドAmbrx, Inc. Humanized anti-prostate specific membrane antigen (PSMA) antibody drug conjugate
JP2021523147A (en) 2018-05-09 2021-09-02 レゲネロン ファーマシューティカルス，インコーポレーテッド Anti-MSR1 antibody and how to use it
JP2021524740A (en) 2018-05-18 2021-09-16 グリコトープ ゲーエムベーハー Anti-MUC1 antibody
CN109321510B (en) * 2018-09-29 2021-08-20 昆明理工大学 Application of strigolactone in promoting accumulation of grease of monocladium algae
CN110174363A (en) * 2019-01-09 2019-08-27 北京九强生物技术股份有限公司 Glucose-6-phosphate dehydrogenase mutant and its purposes in preparation detection reagent
CN112219794B (en) * 2020-09-03 2022-03-04 北京大学第一医院 Method for establishing bronchopulmonary dysplasia animal model by using perfluorooctanoic acid

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
FR2504010B1 (en) 1981-04-15 1985-10-25 Sanofi Sa ANTI-CANCER MEDICINAL PRODUCTS CONTAINING THE RICIN-ASSOCIATED CHAIN ASSOCIATED WITH ANTIMELANOMA ANTIBODY AND PROCESS FOR THEIR PREPARATION
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
ATE66469T1 (en) 1985-01-14 1991-09-15 Neorx Corp METAL RADIONUCLIDE LABELED PROTEIN FOR DIAGNOSIS AND THERAPY.
US4824659A (en) 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
IN165717B (en) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
KR0162259B1 (en) 1989-12-05 1998-12-01 아미 펙터 Chimeric antibody for detection and therapy of infectious and inflammatory lesions
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5189178A (en) 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
EP0643583B1 (en) 1992-05-06 2000-07-26 Immunomedics, Inc. Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6150508A (en) 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6558669B1 (en) 1996-08-28 2003-05-06 Immunomedics, Inc. Stable radioiodine conjugates and methods for their synthesis
DK0932417T3 (en) 1996-10-17 2003-04-14 Immunomedics Inc Non-antigenic toxin conjugate and fusion protein of internalizing receptor system
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
PL334840A1 (en) 1997-01-24 2000-03-27 Univ California Application of fxr, pparalpha and lxralpha activators in order to restore the barrier function, to stimulate epithelium differentation and to inhibit proliferation
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6187284B1 (en) 1997-09-03 2001-02-13 Immunomedics, Inc. Fluorination of proteins and peptides for F-18 positron emission tomography
AU2546399A (en) 1998-02-10 1999-08-30 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
ATE279430T1 (en) 1998-03-05 2004-10-15 Chiron Corp METHOD FOR IMPROVING THE SERUM HALF-LIFE OF BIOLOGICALLY ACTIVE MOLECULES
US6071490A (en) 1998-05-07 2000-06-06 Immunomedics, Inc. Position emission tomography using gallium-68 chelates
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
EP1115853A2 (en) 1998-09-23 2001-07-18 Ludmila Solomin Analysis of ligand activated nuclear receptors in vivo
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
ES2326850T3 (en) 1998-12-23 2009-10-20 Glaxo Group Limited TESTS FOR NUCLEAR RECEPTORS LIGANDOS.
US6071955A (en) 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
AU780658B2 (en) 1999-03-26 2005-04-07 City Of Hope Method of affecting cholesterol catabolism using nuclear bile acid receptor
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
TR200200440T2 (en) 1999-06-18 2002-09-23 Cv Therapeutics, Inc. Compositions and methods to increase the outflow of cholesterol and increase HDL using ATP Binding Cassette Transporter Protein ABC1
AU2000235960A1 (en) 2000-02-14 2001-08-27 Tularik, Inc. Lxr modulators
WO2001082917A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Treatment of hypertriglyceridemia and other conditions using lxr modulators
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2003024388A2 (en) 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
EP3184539A3 (en) 2001-10-23 2017-09-13 PSMA Development Company L.L.C. Psma antibodies
CA2478012C (en) 2002-03-01 2012-06-19 Immunomedics, Inc. Internalizing anti-cd74 antibodies and methods of use
EP1551505B1 (en) 2002-10-04 2010-02-24 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
EP1636340A4 (en) * 2003-06-18 2009-02-11 Scripps Research Inst Unnatural reactive amino acid genetic code additions
US7259240B2 (en) 2003-10-31 2007-08-21 The Regents Of The University Of California Primate prokineticin receptor polypeptides
US7837980B2 (en) * 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
EP1756166A4 (en) 2004-04-19 2008-08-27 Proscan Rx Pharma Prostate cancer diagnosis and treatment
DK1812031T3 (en) 2004-11-01 2015-09-14 Univ California Compositions and methods for the modification of biomolecules
JP5249587B2 (en) 2005-02-18 2013-07-31 メダレックス， インク． Monoclonal antibody against prostate specific membrane antigen (PSMA) lacking fucosyl residues
DK3332808T3 (en) 2005-03-03 2020-12-14 Immunomedics Inc Humanized L243 antibodies
JP5011277B2 (en) 2005-04-06 2012-08-29 アイビーシー・ファーマシューティカルズ・インコーポレーテッド Methods and uses for generating stably linked complexes consisting of homodimers, homotetramers or dimeric dimers
CA2612762C (en) * 2005-06-20 2013-12-10 Psma Development Company, Llc Psma antibody-drug conjugates
JP2009537530A (en) 2006-05-15 2009-10-29 ウィスコンシン・アルムニ・リサーチ・ファウンデーション Pulmonary delivery of 1α, 25-dihydroxyvitamin D3 and simultaneous administration of parathyroid hormone or calcitonin
FR2902092B1 (en) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli LOAD HANDLING APPARATUS
CN101657190B (en) 2007-04-19 2013-09-11 东亚制药株式会社 A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
EP2727606A3 (en) * 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
EP3170821B1 (en) * 2011-05-27 2021-09-15 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives

Also Published As

Publication number Publication date
EP2861259A1 (en) 2015-04-22
KR20150023729A (en) 2015-03-05
US20150152187A1 (en) 2015-06-04
IL236147A0 (en) 2015-01-29
CN104619350A (en) 2015-05-13
CA2876706A1 (en) 2013-12-19
JP2015521602A (en) 2015-07-30
AU2013274078A1 (en) 2015-01-29
WO2013188740A1 (en) 2013-12-19
MX2014015205A (en) 2015-08-14

Similar Documents

Publication Publication Date Title
SG11201408347UA (en) Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201907580SA (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201900201YA (en) Methods for quantitating individual antibodies from a mixture
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201407564TA (en) St2 antigen binding proteins
SG11201408161RA (en) Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201805420SA (en) Antibodies and conjugates thereof
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201407561UA (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
SG11201809252YA (en) Methods for determining dpp3 and therapeutic methods
SG11201806121PA (en) Ror2 antibody compositions and related methods